Biogen (BIIB) News Today

Biogen Inc. (NASDAQ: BIIB) shares decreased as investors weighed a strong third-quarter operating performance against a GAAP loss, higher costs, and concerns that recent gains may already reflect much of the company’s growth outlook.

• Positive Sentiment: Biogen reported adjusted third-quarter earnings of $2.62 per share, well above analyst expectations of roughly $1.99–$2.06, while revenue rose 10.6% year over year to $2.80 billion, also exceeding estimates. Biogen third-quarter earnings report
• Positive Sentiment: The newer growth portfolio continued to offset pressure on older multiple sclerosis products, with revenue increasing 49% to $1.26 billion. Rare-disease revenue rose 27% to $676 million, helped in part by the first full quarter of products acquired through Apellis. Biogen Q3 revenue and earnings update
• Positive Sentiment: Biogen raised the lower end of its 2026 adjusted EPS guidance to $12.20, producing a new range of $12.20 to $13.00. Needham and Baird subsequently raised their price targets to $290 and assigned bullish “buy” and “outperform” ratings, respectively. Analyst forecasts for Biogen
• Neutral Sentiment: Biogen plans to present additional Alzheimer’s disease data at CTAD 2026, including long-term CELIA study data for diranersen and extended real-world and clinical evidence for lecanemab. The presentations could provide future pipeline catalysts, but the data will not affect near-term earnings. Biogen CTAD 2026 announcement
• Negative Sentiment: Despite the adjusted-profit beat, Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, compared with a profit of $466.5 million a year earlier. The loss primarily reflected transaction-related expenses, including $284 million of acquired research and development costs tied largely to the RayThera acquisition. Biogen GAAP loss report
• Negative Sentiment: Barclays raised its price target to $230 but retained an “equal weight” rating, leaving its target below the current trading level. Unusually heavy put-option activity also indicated increased near-term hedging or bearish speculation. Barclays Biogen rating